Katherine Cahill is a Rheumatology/Immunology physician. OpenAlex indexes 151 publications with 3,499 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2611 West End Avenue Room 210
Nashville, TN 37232
Telephone
615-936-2727Provider last certified this registry record 16 Mar 2022.
Clinical trials
- Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Sponsor: Vanderbilt University Medical Center
- Prostaglandin E2 as a Critical Mediator of Sex Disparities in Asthma
Sponsor: Vanderbilt University Medical Center
- Role of Inflammatory Mediators in AERD
Sponsor: Brigham and Women's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20255 payments
- Boehringer Ingelheim International GmbHProgram year202511 payments
- GENZYME CORPORATIONProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- GLP-1R agonist immune targets in lean and obesity-associated asthma
Vanderbilt University Medical Center
FY2026$745,797R01AI182159 - Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
Vanderbilt University Medical Center
FY2025$1,583,667U01AI155299 - GLP-1R agonist immune targets in lean and obesity-associated asthma
Vanderbilt University Medical Center
FY2025$745,797R01AI182159
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement
World Allergy Organization Journal
2025 - Androgen signaling restricts glutaminolysis to drive sex-specific Th17 metabolism in allergic airway inflammation
Journal of Clinical Investigation
2024 - Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes
American Journal of Respiratory and Critical Care Medicine
2023 - Liraglutide pretreatment attenuates sepsis-induced acute lung injury
American Journal of Physiology-Lung Cellular and Molecular Physiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”